immunocore-logo-2018
Immunocore Reports First Quarter 2021 Financial Results
May 12, 2021 07:00 ET | Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...
Immunocore1.png
Immunocore announces key appointments to management and Board
February 16, 2021 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
Immunocore1.png
Immunocore announces closing of $75.0 Million Series C round
January 11, 2021 07:00 ET | Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...